Holly Schachner
Directeur Technique/Scientifique/R&D chez DoubleRainbow Biosciences, Inc.
Profil
Holly Schachner is currently the Chief Medical Officer at DoubleRainbow Biosciences, Inc. She previously worked as the Lead Independent Director at Applied Molecular Transport, Inc. from 2021 to 2023, Senior Vice President-Clinical Science Therapeutic at MyoKardia, Inc. from 2020 to 2021, Head-Diabetes & Cardiovascular Business Unit at Sanofi SA from 2016 to 2019, and Chief Medical Officer-Global Specialty Medicine at Allergan Ltd.
(Ireland) from 2019 to 2020.
Dr. Schachner holds a doctorate degree from Stony Brook School and an undergraduate degree from the University of Michigan.
Postes actifs de Holly Schachner
| Sociétés | Poste | Début |
|---|---|---|
DoubleRainbow Biosciences, Inc.
 DoubleRainbow Biosciences, Inc. BiotechnologyHealth Technology DoubleRainbow Biosciences, Inc. engages in the development of transformative technologies. It explores essential natural ingredients that enhance daily experience and health through food, beverages, cosmetics, supplements, and other consumer products. The company was founded by Jing Ke Weng and Tian Xu and is headquartered in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 01/08/2021 |
Anciens postes connus de Holly Schachner
| Sociétés | Poste | Fin |
|---|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Directeur/Membre du Conseil | 27/12/2023 |
| MYOKARDIA, INC. | Corporate Officer/Principal | 01/04/2021 |
| ALLERGAN PLC | Corporate Officer/Principal | 01/07/2020 |
| Sanofi SA | Corporate Officer/Principal | 01/01/2019 |
Formation de Holly Schachner
| University of Michigan | Undergraduate Degree |
| Stony Brook School | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| APPLIED MOLECULAR TRANSPORT INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
DoubleRainbow Biosciences, Inc.
DoubleRainbow Biosciences, Inc. BiotechnologyHealth Technology DoubleRainbow Biosciences, Inc. engages in the development of transformative technologies. It explores essential natural ingredients that enhance daily experience and health through food, beverages, cosmetics, supplements, and other consumer products. The company was founded by Jing Ke Weng and Tian Xu and is headquartered in Cambridge, MA. | Health Technology |
MyoKardia, Inc.
 MyoKardia, Inc. Pharmaceuticals: MajorHealth Technology MyoKardia, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, commercialization, and development of therapies for the treatment of cardiovascular diseases. Its lead therapeutic candidate, Mavacamten, is an orally administered allosteric modulator of cardiac myosin being developed for the treatment of hypertrophic cardiomyopathy (HCM). The company was founded by James A. Spudich, Jonathan G. Seidman, Christine Seidman, and Leslie Leinwand on June 8, 2012 and is headquartered in South San Francisco, CA. | Health Technology |
Allergan Ltd. (Ireland)
 Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
| Sanofi SA | Health Technology |